RICHMOND, Va., June 26, 2002 (PRIMEZONE) -- Biotechnology and Immunotherapy company AVANT Immunotherapeutics will discuss prospects and strategies at the Biotechnology/Disease Prevention Stocks Form on Friday, June 28. This online Forum, free to investors, is accessible at www.informedinvestors.com from 9 a.m.-10 a.m. EST. Investors have the opportunity to hear directly from company executives and get their investment information straight from the source.
The Informed Investors Forum will have senior executives from AVANT Immunotherapeutics (Nasdaq:AVAN), speaking for approximately 30 minutes with PowerPoint presentations. Investors are invited to email questions to executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of vaccines to prevent and treat disease. The company is conducting clinical studies of a proprietary vaccine candidate for cholesterol management. The company is also developing a broad portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines aimed at protecting travelers from Cholera, Typhoid fever, Shigella, ETEC and Campylobacter. AVANT further leverages the value of its technology portfolio through corporate partnerships. Current collaborations include the development of an oral human rotavirus vaccines, vaccines to combat threats of biological warfare and vaccines addressed to human food safety.
Recently AVANT announced they had received a US Patent covering their novel vaccine for cholesterol management, CETi-1. The CETi-1 vaccine induces antibodies against a portion of the cholesteryl ester transfer protein (CETP), a serum protein responsible for cholesterol transfer from high-density lipoprotein (HDL) cholesterol to low-density lipoprotein cholesterol (LDL). In doing so, the vaccine blocks the ability of CETP to shuttle cholesterol from HDL to LDL, thus potentially causing blood serum levels of the heart-protective HDL cholesterol to rise.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink suite of PrecisionIR(tm) services serving publicly traded companies and self-reliant investors.
About WILink: Since 1992, WILink (www.wilink.com) has opened information channels between public companies and potential investors. This year WILink will make more than 7 million investor introductions to over 4,600 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and webcast investor events and financial reports through WILink's relationships with over 220 leading financial media channels including The Wall Street Journal, Financial Times, Barron's and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions.
WILink, Inc. a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange) began operations in Richmond, Va. in 1993.